{"id":21416,"date":"2024-06-08T09:39:09","date_gmt":"2024-06-08T09:39:09","guid":{"rendered":"https:\/\/clinlabint.com\/?p=21416"},"modified":"2024-05-28T09:48:55","modified_gmt":"2024-05-28T09:48:55","slug":"teva-uk-and-closed-loop-medicine-collaborate-to-advance-development-of-personalised-medicines","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/teva-uk-and-closed-loop-medicine-collaborate-to-advance-development-of-personalised-medicines\/","title":{"rendered":"Teva UK and Closed Loop Medicine collaborate to advance development of personalised medicines"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Teva UK and Closed Loop Medicine collaborate to advance development of personalised medicines<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Teva UK and Closed Loop Medicine will collaborate to advance the development of personalised medicine. Under the agreement, Closed Loop Medicine \u2013 a leading TechBio company \u2013 and Teva UK \u2013 a pharmaceutical company, will investigate opportunities to use Closed Loop Medicine\u2019s proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalised medicines, improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.<\/h3>\n

<\/p>\n

Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine, said: \u201cAs clinicians, we know that dosing of drugs is a huge problem. In the most extreme cases, we are seeing patients having severe adverse events, for example
\nwhen required to change dose levels to undergo surgery. Being able to predict personalised dose levels could be transformational.\u201d<\/p>\n

This strategic partnership harnesses Closed Loop Medicine\u2019s proprietary SaMD and combines it with Teva\u2019s pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.<\/p>\n

Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology\u2019s ability to dose optimise drug therapy and minimise side effects whilst achieving blood pressure control, with exceptionally high medication adherence. [1]<\/p>\n

Personalised medicine is an aspiration of the modern healthcare system, yet existing medicines are typically prescribed based on their average effects in a population and rarely dose optimised for the individual. This \u201cone size fits all\u201d approach results in increased side effects and adverse reactions, medication non-adherence and consequently poorer patient outcomes and higher healthcare costs for payors. For example, the annual cost of drug-related morbidity and mortality resulting from non-optimised medication was estimated at $528.4 billion in the US, in 2016, [2] and the projected annual cost of adverse drug reactions alone to the NHS is \u00a32.21 billion. [3] Kim Innes, Teva\u2019s General Manager, UK & Ireland, said: \u201cWe are excited to be working with Closed Loop Medicine, who have demonstrated themselves to be compelling innovators in the area of personalised medicine. We know that the patient experience can sometimes be less than optimal and as the largest supplier of medicines to the NHS, the potential to combine \u2018drug\u2019 & \u2018digital\u2019 could create significant improvements to lives of patients at great scale. We are very excited about the future of this partnership.\u201d<\/p>\n

Dr Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine, commented: \u201cIt is a fantastic opportunity to be working with the Teva team to explore ways in which our combined expertise can advance the delivery of personalised medicine solutions, globally.\u201d<\/p>\n

He added: \u201cThe integration of real-world data enables personalisation of dosing that has historically not been readily available to clinicians before. This commercial partnership is an example of the potential and scalability of our SaMD technology platform, demonstrating the value that can be added by integrating software to well-known and trusted brands to improve disease management and patient outcomes at an individual level.\u201d<\/p>\n

References:<\/strong>
\n1. Collier DJ, Taylor M, Godec T, et. al. Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial). J Am Heart Assoc. 2024 Feb 20;13(4):e030749. doi: https:\/\/doi.org\/10.1161\/JAHA.123.030749<\/a> <\/em>
\n2. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug\u2013Related Morbidity and Mortality. Annals of Pharma\u00adcotherapy. 2018;52(9):829-837. doi: https:\/\/doi.org\/10.1177\/1060028018765159<\/a> <\/em>
\n3. Osanlou R, Walker L, Hughes DA, et. al. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of <\/em>1 month of medical admissions. BMJ Open 2022;12:e055551. doi: https:\/\/doi.org\/10.1136\/bmjopen-2021-055551<\/a><\/em><\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine<\/em><\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Kim Innes, Teva\u2019s General Manager, UK & Ireland<\/em><\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Dr Hakim Yadi OBE, CEO & Co-Founder of Closed Loop Medicine<\/em><\/p>\n<\/div><\/section>
\n